

RESEARCH ARTICLE

COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience

Federica Alemanno¹, Elise Houdayer^{1*}, Anna Parma¹, Alfio Spina², Alessandra Del Forno¹, Alessandra Scatolini¹, Sara Angelone¹, Luigia Brugliera¹, Andrea Tettamanti¹, Luigi Beretta³, Sandro Iannaccone¹

1 Department of Rehabilitation and Functional Recovery, IRCCS San Raffaele Scientific Institute, Milan, Italy, **2** Department of Neurosurgery and Gamma Knife Radiosurgery, IRCCS San Raffaele Scientific Institute, Milan, Italy, **3** Department of General Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy

* houdayer.elise@hsr.it



Abstract

Introduction

COVID-19 complications can include neurological, psychiatric, psychological, and psychosocial impairments. Little is known on the consequences of SARS-COV-2 on cognitive functions of patients in the sub-acute phase of the disease. We aimed to investigate the impact of COVID-19 on cognitive functions of patients admitted to the COVID-19 Rehabilitation Unit of the San Raffaele Hospital (Milan, Italy).

Material and methods

87 patients admitted to the COVID-19 Rehabilitation Unit from March 27th to June 20th 2020 were included. Patients underwent Mini Mental State Evaluation (MMSE), Montreal Cognitive Assessment (MoCA), Hamilton Rating Scale for Depression, and Functional Independence Measure (FIM). Data were divided in 4 groups according to the respiratory assistance in the acute phase: Group1 (orotracheal intubation), Group2 (non-invasive ventilation using Biphase Positive Airway Pressure), Group3 (Venturi Masks), Group4 (no oxygen therapy). Follow-ups were performed at one month after home-discharge.

Results

Out of the 87 patients (62 Male, mean age 67.23 ± 12.89 years), 80% had neuropsychological deficits (MoCA and MMSE) and 40% showed mild-to-moderate depression. Group1 had higher scores than Group3 for visuospatial/executive functions ($p = 0.016$), naming ($p = 0.024$), short- and long-term memory ($p = 0.010$, $p = 0.005$), abstraction ($p = 0.024$), and orientation ($p = 0.034$). Group1 was younger than Groups2 and 3. Cognitive impairments correlated with patients' age. Only 18 patients presented with anosmia. Their data did not differ from the other patients. FIM (<100) did not differ between groups. Patients partly recovered at one-month follow-up and 43% showed signs of post-traumatic stress disorder.

OPEN ACCESS

Citation: Alemanno F, Houdayer E, Parma A, Spina A, Del Forno A, Scatolini A, et al. (2021) COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience. PLoS ONE 16(2): e0246590. <https://doi.org/10.1371/journal.pone.0246590>

Editor: Francesco Di Gennaro, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, ITALY

Received: November 6, 2020

Accepted: January 22, 2021

Published: February 8, 2021

Copyright: © 2021 Alemanno et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: The authors received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Conclusion

Patients with severe functional impairments had important cognitive and emotional deficits which might have been influenced by the choice of ventilatory therapy, but mostly appeared to be related to aging, independently of FIM scores. These findings should be integrated for correct neuropsychiatric assistance of COVID-19 patients in the subacute phase of the disease, and show the need for long-term psychological support and treatment of post-COVID-19 patients.

Introduction

The coronavirus disease 2019 (COVID-19) pandemic has dramatically shaken the healthcare system, worldwide, leading in January 2021 to up to 90 million cases and nearly 2 million deaths (source: World Health Organization Coronavirus Disease dashboard). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the COVID-19 can be responsible for various clinical features, ranging from asymptomatic to critical health conditions. Among these features, the most common forms are: (1) mild, with no dyspnea, no low blood oxygen saturation (SatO₂); (2) moderate, with dyspnea, SatO₂ = 94% to 98%, radiological signs of pneumonia; (3) severe, with dyspnea, SatO₂ ≤ 93%, respiratory rate (RR) > 30/min, radiological progression of lesions, with O₂ supplementation required, eventually with non-invasive ventilation; and (4) critical with patients needing mechanical ventilation [1]. In all these various clinical conditions, patients can present with cardiorespiratory, neurologic or systemic complications, leading to the need for functional rehabilitation for about 20% of hospitalized COVID-19 patients [1–4]. Nonetheless, in the first months, hospitals tended to discharge patients as soon as possible to face the increasing needs for hospital admissions. A communication from the San Raffaele Hospital of Milan reported that, in the exponential phase of the national pandemic, about 25% of patients needed specialized rehabilitation to address cardiorespiratory, motor and/or cognitive dysfunctions in the subacute phase [4]. Indeed, in this subacute phase (from five to twenty days after symptoms onset), patients are still infectious for COVID-19 and can be in need for functional rehabilitation. The clinical care of these patients should be organized according to the clinical status and symptoms of the patients. Recommendations have been addressed to support the implementation of a multidisciplinary rehabilitative pathway for those COVID-19 patients in need for functional recovery [1, 4]. According to this new organization, COVID-19 patients with functional deficits (with positive swab and no need for ICU) should be transferred to dedicated COVID-19 rehabilitation units when they meet the following criteria: stable for at least three days (no recurrence of fever, both respiratory rates (RR) and SatO₂ stable, radiological progression of the disease has been ruled out) and Functional Independence Measure (FIM) shows areas of dependence (score < 100 [5]). Neurological complications of the COVID-19, such as dizziness, headache, ageusia or anosmia, have been described [6–8]. Patients can also suffer from signs of deconditioning, critical-illness-related myopathy and neuropathy (CRIMYNE), dysphagia, joint stiffness, and pain [1]. It has also been recently shown that patients can present sub-clinical signs of neuronal suffering, even in the absence of neurological symptoms [9]. Psychiatric complications have also been reported, such as encephalitis, cerebrovascular disease (ischemic stroke or intracerebral hemorrhage), psychosis or neurocognitive syndrome (dementia-like) [6, 10–13].

Reports have also been made on the psycho-social effects of the COVID-19 pandemic on patients, caregivers and on the general population in relation with home-confinement. Most

of these communications reported issues related to anxiety, depression, and post-traumatic stress syndrome [14, 15].

Although neurological, psychiatric, and psychological signs have been reported in COVID-19 patients, there is a lack of data regarding the actual consequences of the disease on the cognitive functions in patients still presenting signs of SARS-CoV-2 infection. In this study, we aimed to investigate the impact of COVID-19 on the cognitive functions of infectious patients admitted to the COVID-19 Rehabilitation Unit of the San Raffaele Scientific Institute of Milan (Italy), in the sub-acute phase of the disease (about ten days after symptoms onset). For data analysis, patients were separated in four different groups according to the type of respiratory assistance they benefited in the acute phase of the disease.

Materials and methods

Population

Oral and written consents were obtained from participants, in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and the study was approved by our local Ethics committee. Consecutive patients admitted to the COVID-19 Rehabilitation Unit of the San Raffaele Scientific Institute (Milan) from March 27th to June 20th 2020 have been included. Criteria to admit COVID-19 patients in this Unit were: positive swab for SARS-CoV-2, stable SatO₂ and RR, no need for respiratory assistance or no more than two l/min, absence of fever, and with areas of dependence at the FIM evaluation (FIM score < 100) [4]. These patients had been previously admitted in the Emergency Room (ER), Intensive Care Units (ICU), Respiratory High Dependency Care Units (RHDCU) or Infectious Diseases units of the San Raffaele Hospital. We excluded from the subsequent clinical study patients who were treated for cognitive dysfunctions, patients who were under psychotropic drugs prior to their recovery, and patients presenting with COVID-19 encephalitis. Patients with a disease onset less than five days and superior to 20 days were also excluded (patients were thus in the sub-acute phase of the disease, five to twenty days after symptoms onset).

Evaluations and measurements

At their admission in the COVID-19 Rehabilitative Unit, patients underwent neuropsychological evaluation including: Mini Mental State Evaluation (MMSE) [16], Montreal Cognitive Assessment (MoCA) [17], and Hamilton Rating Scale for Depression (HRSD) [18]. No further detailed neuropsychological testing could have been done, giving the clinical conditions of patients. Patients were asked about history of anosmia during the acute phase. There were no clinical measurements of olfaction, due to the poor compliance of patients. Patients underwent FIM evaluation with a physiotherapist [5]. Some of these patients were subjected to a cerebral MRI with contrast or CT scan during their recovery, on the basis of clinical needs. In this case, three different investigators individually evaluated the cerebral images to assess cerebral trophism. Global cerebral atrophy (GCA) was evaluated on CT or MRI scans, based on fluid attenuated inversion recovery (FLAIR) acquisitions. Inter-observer results were standardized to obtain a single value [19]. GCA resulted from a systematic evaluation of 13 different regions of the brain to determine sulcal dilatation and dilatation of the ventricular system. At each level, a score of 0 (absent), 1 (mild), 2 (moderate) and 3 (severe) was given. The GCA resulted from the sum of all items (from 0 to 39) [19, 20]. White matter lesions (WML) were also analyzed on FLAIR acquisitions, with the Fazekas scale to assess white matter hyperintense lesions related to small vessels disease [21]. This scale consisted of a score of 0 (no or single WML), 1 (multiple WML), 2 (beginning confluence of WML), or 3 (large confluent WML) [21]. A Fazekas score of 1 is considered normal in the elderly, while Fazekas 2 and 3 are usually considered

pathologic. Scores of 2 or 3, when seen in normally functioning individuals, can be correlated with a high risk of disability [22].

Follow-ups

Patients were discharged and returned their homes after rehabilitation only with two consecutive negative swabs, at 24 hours interval. Patients were proposed follow-up (FU) visits, one month after hospital discharge. At FU, the following neuropsychological tests were performed: MMSE, MoCA, HRSD and the Davidson Trauma Scale [23] (DTS) to investigate possible post-traumatic stress syndrome.

Data analysis

Patients were divided in four groups according to the respiratory support they received in the acute phase of the disease. Oxygen saturation (SpO₂), partial pressure of carbon dioxide (PaCO₂), pH and respiratory rate were used to define the respiratory intervention. Group 1 included patients who benefited from orotracheal intubation and ventilation from one to twenty-seven days (mean duration of intubation 12.39 ± 6.51 days). The following criteria were used to decide intubation and ventilation: tachypnoea, (RR>35), tachycardia, fatigue, agitation, use of accessory muscles, intercostal recession, SpO₂>90, PacO₂ > 60 mmHg, pH < 7.30. Group 2 included patients who benefited from non-invasive ventilation (NIV) using Biphasic Positive Airway Pressure (BiPAP or CPAP). Group 3 included patients who received oxygen therapy with Venturi Masks or reservoir Masks. Oxygen therapy was started with the aim to maintain SpO₂ >90%, first, with Venturi Masks up to fiO₂ 50% (fraction of inspired oxygen), then with reservoir Masks up to fiO₂ 70%. Group 4 did not receive any oxygen therapy during the acute phase of the disease.

Statistical analyses

Data from the different groups were analyzed using either one-way ANOVA or Kruskal-Wallis test, depending on the normality of data distribution, as evaluated by the Shapiro-Wilk test. Post-hoc analyses were performed using t-tests for independent values or Mann-Whitney analyses, depending on normality of the data. Bonferroni correction for multiple testing was applied. Spearman non-parametric correlation tests were used to investigate correlations between two variables. Follow-up data were compared to data at admission using Wilcoxon analyses. Data were considered significant when $p < 0.05$. The commercially available software IBM SPSS Statistics v.23 (IBM Corp. ©) was used for all statistical tests.

Results

Patients' description

About 140 patients have been admitted in the COVID-19 Rehabilitation Unit during the above-mentioned period (about 80 days). These patients represented about 20% of the total number of COVID-19 patients hospitalized in the acute care units of the San Raffaele Scientific Institute (Milan, Italy). Out of these 140 patients, 87 met the inclusion criteria and were included in the study. Out of the 87 patients (62 Male, 25 Female, mean age 67.23 ± 12.89 years), 31 belonged to Group 1 (five Female, 26 Male, mean age 59.90 ± 8.92 years), 18 belonged to Group 2 (four Female, 14 Male, mean age 72.61 ± 8.15 years), 29 were included in Group 3 (14 Female, 15 Male, mean age 73.17 ± 12.19 years) and nine were included in Group 4 (two Female, seven Male, mean age 62.56 ± 20.06 years). Kruskal-Wallis analyses indicated a

significant effect of the main factor age ($p < 0.001$). Indeed, the mean age of Group 1 was significantly lower than the mean age of Group 2 ($p < 0.006$) and Group 3 ($p < 0.006$).

Neuropsychological data–infectious patients

The analyses of the MoCA scores showed that 74.2% of patients from Group 1, 94.4% of patients from Group 2, 89.6% of patients from Group 3 and 77.8% of patients from Group 4 presented with deficits, as shown by the analysis of the total score. One-way ANOVA on the main factor “total score” showed significant group differences ($p = 0.006$) (Table 1). Specifically, Group 1 presented with higher scores compared to Group 3 ($p = 0.005$, see Fig 1). Significant differences between these two groups were observed in the sub-domains of short-term memory ($p = 0.010$), attention ($p = 0.016$), abstraction ($p = 0.024$), long-term memory ($p = 0.005$), space and time orientation ($p = 0.034$).

MMSE analyses showed that 12.9% of patients from Group 1 had mild to severe deficits; 55.6% of patients from Group 2 had mild to moderate deficits; 48.3% of patients from Group 3 had mild to severe deficits; and 44.4% from Group 4 presented with moderate deficits. Kruskal-Wallis analyses showed significant differences between groups ($p = 0.021$, Fig 1). Group 1 presented with higher scores compared to Group 3 ($p = 0.024$). These differences were significant in the attention and calculation domain ($p = 0.003$), in the memory domain ($p = 0.017$), and in the language domain ($p = 0.024$). There was also a trend towards differences in the temporal orientation sub-domain ($p = 0.051$).

Taken all groups together, MMSE total scores and MoCA total scores correlated significantly with patients’ age (MMSE: $R = -0.262$, $p = 0.014$; MoCA: $R = -0.376$, $p < 0.001$, see Fig 2).

Table 1. Neuropsychological and FIM evaluation of COVID-19 patients.

		GROUP 1	GROUP 2	GROUP 3	GROUP 4
MoCA	Total score (/30)	21.65 ± 5.23 *	16.83 ± 7.11	15.90 ± 6.97 *	19.11 ± 6.83
	Visuospatial/Executive	2.83 ± 1.60	2.19 ± 1.47	2.16 ± 1.75	3.33 ± 1.86
	Naming	2.77 ± 0.57	2.50 ± 0.82	2.40 ± 0.96	2.67 ± 0.82
	Short-term memory	4.63 ± 1.00 *	3.94 ± 1.29	4.04 ± 1.21 *	4.17 ± 1.60
	Attention	4.83 ± 1.64 *	4.13 ± 1.78	3.68 ± 2.34 *	5.00 ± 2.45
	Language	1.67 ± 1.12	1.44 ± 1.15	1.28 ± 0.94	2.33 ± 1.03
	Abstraction	1.20 ± 0.71 *	0.69 ± 0.79	0.72 ± 0.74 *	1.00 ± 0.63
	Long-term Memory	2.00 ± 1.51 *	1.06 ± 1.65	1.08 ± 1.50 *	1.17 ± 1.47
	Orientation	5.27 ± 1.23 *	4.44 ± 1.67	4.80 ± 1.35 *	4.17 ± 2.40
MMSE	Total score (/30)	26.77 ± 2.77 *	22.78 ± 5.80	22.24 ± 6.23 *	22.89 ± 6.97
	Temporal Orientation	4.47 ± 0.57	3.53 ± 1.38	3.92 ± 1.44	3.29 ± 1.70
	Spatial Orientation	4.63 ± 0.62	4.41 ± 0.62	4.16 ± 1.14	4.43 ± 0.78
	Retention	2.93 ± 0.25	2.82 ± 0.39	2.84 ± 0.47	2.71 ± 0.76
	Calculation/Attention	4.50 ± 1.11 *	3.59 ± 1.84	3.64 ± 1.66 *	3.57 ± 2.44
	Memory Recall	2.33 ± 0.76 *	1.76 ± 1.09	1.68 ± 1.28 *	2.00 ± 1.16
	Language	7.20 ± 0.93 *	6.94 ± 1.20	6.64 ± 1.25 *	7.00 ± 1.16
	Visuospatial	0.63 ± 0.49	0.53 ± 0.51	0.40 ± 0.50	0.57 ± 0.53
HRSD	Total score (/52)	6.65 ± 4.33	6.56 ± 4.03	6.86 ± 4.01	7.13 ± 5.33
FIM	Total score	55.79 ± 33.38	64.50 ± 45.78	71.64 ± 39.38	62.75 ± 19.21

Scores are divided according to each Group.

* represents significant differences between groups ($p < 0.05$). MoCA = Montreal Cognitive Assessment. MMSE = Mini Mental State Examination. HRSD = Hamilton Rating Scale for Depression. FIM = Functional Independence Measure.

<https://doi.org/10.1371/journal.pone.0246590.t001>




Fig 1. MoCA, MMSE and HRSD total scores. Fig 1 represents the values of the MoCA, MMSE, and HRSD total scores according to the different groups. * = $p < 0.05$. HRSD = Hamilton Rating Scale for Depression.

<https://doi.org/10.1371/journal.pone.0246590.g001>

Hamilton Rating Scale for Depression showed that 45.2% of patients from Group 1 had mild to moderate depression, 33.3% of patients from Group 2 had mild depression, 37.9% of patients from Group 3 had mild depression and 44.4% of patients from Group 4 had mild to moderate depression. There were no significant differences between groups in terms of total scores ($p > 0.05$, see Table 1). There was no significant correlation between patients' age and depression score ($R = -0.048$, $p = 0.663$, see Fig 2).

One-month follow-up

56 patients (22 of Group 1, 12 of Group 2, 20 of Group 3 and 2 of Group 4) underwent the follow-up evaluations, one month after discharge.

MoCA analyses showed that, at FU, 12 out of the 22 patients from Group 1 (54.5%) had deficits; 10 out of the 12 patients from Group 2 (83.3%) had deficits; 17 out of 20 patients of Group 3 (85%) had deficits; and the 2 patients from Group 4 presented with deficits (100%). Although many patients still presented deficits at the MoCA evaluation, MoCA total scores at FU were however significantly higher than at admission ($p = 0.009$).

Conversely, MMSE analyses showed that, at FU, only 2 out of 22 patients from Group 1 (9.1%) had mild deficits; 1 out of 12 patients from Group 2 (8.3%) had mild deficits; 7 out of 20 patients of Group 3 (35%) had mild to moderate deficits; and 1 out of the 2 patients from Group 4 presented with moderate deficits. In concordance with such clinical improvements, MMSE total scores at admission and at 1-month FU differed significantly ($p = 0.004$).

Regarding the analyses of HRSD at FU, 4 out the 22 patients of Group 1 (18.2%) had mild depression, 4 out the 12 patients of Group 2 (33.3%) had mild to moderate depression, 9 out the 20 patients of Group 3 (45%) had mild depression and none of the 2 patients of Group 4 had depression. Depression scores did not differ between FU and time of admission ($p = 0.167$).

Lastly, at FU, 24 patients reported post-traumatic stress disorder symptoms at the Davidson Trauma Scale (12 patients from Group 1, 4 patients from Group 2, 7 patients from Group 3 and 1 patient from Group 4), while 32 reported no disturbances at all.




Fig 2. Neuropsychological values according in the four different groups according to patients' age. Fig 2 represents the dispersion of MoCA, MMSE, and HRSD total scores among the different groups according to patients' age. MoCA = Montreal Cognitive Assessment. MMSE = Mini Mental State Examination. HRSD = Hamilton Rating Scale for Depression.

<https://doi.org/10.1371/journal.pone.0246590.g002>

Neurological signs

Eighteen out of the 87 patients had presented signs of anosmia since the onset of the disease. There were no significant differences in cognitive functions between the group of patients with anosmia and the group of patients who did not suffer from anosmia, either for the MMSE or the MoCA total score ($p = 0.555$ and $p = 0.410$, respectively). FIM scores did not differ either between anosmic and non-anosmic patients ($p = 0.771$).

FIM scores did not significantly differ between groups ($p > 0.05$, see [Table 1](#)), nor correlated with age ($R = -0.048$, $p = 0.187$).

Thirty-seven patients underwent CT head scans or cerebral MRI (14 patients in Group 1, five patients in Group 2, 12 patients in Group 3 and six patients in Group 4). Total CGA scores ranged from 0 to 25 (mean score 8.16 ± 5.85). Patients from Group 1 had a mean CGA score of 5.29 ± 3.50 , patients from Group 2 had a mean score of 9.6 ± 3.78 , patients from Group 3 had a mean score of 11.42 ± 7.59 , and patients from Group 4 a mean score of 7.17 ± 4.96). Kruskal-Wallis analysis showed that there were no significant differences between the four groups ($p = 0.09$). Taken all patients together, there were significant correlations between total CGA scores and the factors age ($R = 0.582$, $p < 0.001$) and MoCA total score ($R = -0.339$, $p = 0.040$). There were no significant differences in GCA scores between patients with or without anosmia ($p = 0.805$).

Discussion

In this communication, we analyzed the neuropsychological data of a group of 87 infectious COVID-19 patients, in the sub-acute phase of the disease, out of about one thousand patients admitted to the ER of our Institution in the last four months. These patients presented with clinical indications for functional rehabilitation (FIM < 100) shortly after the onset of the disease and immediately after the acute phase of the infection.

The great majority of patients were men (71%). All four groups of patients presented similar degrees of depression, with about 40% of patients reporting mild to moderate depression. Moreover, more than 80% of these patients presented with cognitive deficits, as shown by the MoCA analyses. Differential deficits were observed between groups. Indeed, most of these COVID-19 patients had previously benefited from oxygen therapy (57 out of 67), with various degrees of invasiveness. Among patients who previously received oxygen therapy, Group 1 benefited from invasive ventilation and sedation. This group presented with better cognitive status compared to the other groups. There were especially significant differences between this group of patients and Group 3, who received oxygen therapy through Venturi Masks. The cognitive impairments resulted mainly in deficits in short- and long-term memory, executive functions, abstraction, language, and orientation. These data indicate that patients who benefited from the most aggressive respiratory assistance had better preserved cognitive functions in the subacute phase of the disease. However, patients who benefited from the most invasive respiratory assistance were also the youngest. Indeed, Group 1 had a younger mean age compared to groups 2 and 3. This age-difference might have explained, at least in part, the differences in cognitive performance between Groups 1 and 3 (although no significant differences in cognitive functions were observed between Group 1 and Group 2). Cognitive data (MMSE and MoCA total scores) significantly correlated with age. These data indicate that the youngest patients were the ones who benefited from the most invasive respiratory assistance and the ones who showed the most conserved cognitive functions.

Anosmia was reported only in a minority of our patients (18 out of 87). Thus, this neurological sign does not appear to be relevant enough to be used as a screening tool for neurological involvement in hospitalized patients. This low rate of anosmia, compared to previous reports

in the literature [24], might have been influenced by two factors: (1) our patients' population is different from the rest of the evidence reported in the literature as it represents COVID-19 patients hospitalized for functional rehabilitation following the subacute phase of the disease; and (2) the respiratory assistance (either invasive or not) provided to patients. Indeed, oxygen therapy might have biased patients' olfactory sensations, starting from the acute phase of the disease.

Similarly, FIM scores did not differ between groups, showing that the entity of the cognitive deficit was not associated with motor deficits. This result shows that FIM evaluation should be associated with other neurological and neuropsychological testing to better identify neurological dysfunctions in COVID-19 patients.

Similar cognitive deficits are often observed following acute respiratory distress syndrome (ARDS) [25]. 70% to 100% of ARDS survivors would experience cognitive impairments at hospital discharge [26, 27]. Low PaO₂ has been associated with long-term cognitive impairment, especially in the domains of executive functions and psychomotor tasks [28, 29].

MoCA evaluation was more sensitive compared to MMSE to detect these cognitive impairments. As demonstrated in studies on the effects of ARDS, MMSE would have a poor sensitivity in detecting cognitive impairment after ARDS [30]. Thus, implementation of sensitive cognitive testing tools like MoCA may help better assess patients' cognitive functions and, as a consequence, provide better care and functional recovery outcome. Our study showed that MoCA was sensitive enough to detect cognitive impairments of various domains in infectious COVID-19 patients. Other tools previously validated in ARDS studies included the Confusion Assessment Method for Intensive Care Unit patients (CAM-ICU), with a good sensitivity and specificity in detecting delirium [31], or the Modified Blessed Dementia Rating Scale and the Informant Questionnaire on Cognitive Decline in the Elderly to evaluate for pre-existing cognitive deficits [32].

None of our patients presented with delirium, as often observed in ARDS or in post-intensive care syndrome (PICS) [33–36]. PICS can also be accompanied by long-term cognitive impairments, especially regarding memory, executive functions, language, attention, and visual-spatial abilities [33, 36]. Thus, part of our results could be related to PICS, although we showed that patients who benefited from the most invasive respiratory assistance had better preserved cognitive functions and did not show worse mood alterations, compared to the other groups. No signs of psychosis, delirium, or other altered mental status have been observed in these patients.

Our neuropsychological data were unexpected as they showed that patients who underwent sedation and ventilation, i.e. patients in the most critical clinical state, were patients with the less compromised cognitive status. These results might be due to the differences in oxygen volume received during hospitalization. One might also hypothesize that sedation might have spared patients from the stress that such a critical illness might have induced in otherwise conscious patients. Indeed, acute and chronic stress would be associated with increased mechanisms of inflammation and enhanced attentional processing of negative information. Both phenomenon are predictive of depression symptoms that, in turn, increase inflammatory and cognitive stress reactivity [37].

Advanced age appeared to be a relevant factor influencing the cognitive status of patients. Advanced age, together with impaired renal function and elevated C-reactive protein have been reported as major predictors of in-hospital death in a large cohort COVID-19 patients in Italy [38]. Previous reports from our Unit showed a large variety of comorbidities in COVID-19 patients hospitalized in the COVID-19 Rehabilitation Unit, including COVID-19-associated coagulopathy (that led to lower limb amputation in three of our patients), demonstrating the need for a multidisciplinary teams of healthcare professionals [2, 39].

At one-month follow-up, patients from all groups had partly recovered their cognitive impairments, especially as measured by the MMSE. MoCA scores were still showing deficits in most of the patients. These differences observed between MMSE and MoCA scores might be related to the higher sensibility of MoCA to detect slight variations in cognitive functioning, as shown by several studies on Alzheimer or Parkinson's patients [17, 40]. Importantly, 43% of patients tested at one-month follow-up had symptoms of PTSD, especially patients who underwent the most invasive treatments (orotracheal intubation). It had been shown that about 25% of patients admitted into ICU develop PTSD afterwards [41]. Such risk of developing PTSD has been recently shown to be higher in COVID-19 ICU survivors [42]. These data seem to indicate that invasive respiratory treatments represent a more traumatizing experience for patients, in the long-term. Thus, taken altogether, our results report how much patients hospitalized for COVID-19 can present with various cognitive impairments in the sub-acute phase of COVID-19 and how these impairments can persist even one month after discharge, demonstrating the need for psychological treatment and assistance of post COVID-19 patients. The "long-COVID syndrome" is now well-known for including those patients still suffering from various symptoms, weeks, or months after the end of infection [43–45]. Our results show thus that long-term treatments of post-COVID-19 patients should include neuropsychological support and cognitive training, possibly through the use of new technologies, such as telemedicine.

Conclusion

Our study focused on the sub-acute phase of the COVID-19 in positive patients with functional disability, in order to investigate the essential needs of clinical assistance for these patients. Like many healthcare centers worldwide, our Institute has been shaken by the dramatic SARS-CoV-2 pandemic wave. In the exponential phase of the pandemic in Italy (March/April 2020), about 60 patients were admitted in the ER daily. Therefore, all patients in need for respiratory assistance could hardly be admitted to the ICUs, and choices regarding the degree of invasiveness of assistance had to be done. Nowadays, at distance from the emergency pic, the data reported in this paper should serve as a demonstration of how frequent cognitive impairments can be observed in hospitalized COVID-19 patients, and how the types of respiratory assistance can influence the short- and long-term neuropsychological after-effects of the disease, especially in aging patients. Our data showed that about 80% of our patients presented with cognitive deficits in this sub-acute phase of the disease, about 40% of patients suffered from mild to moderate depression, and that these deficits were more important in the older patients. The decisions on respiratory assistance did not have differential consequences on the motor symptoms. The age of patients appeared as a risk factor for neuropsychological impairments due to COVID-19. Since a high number of patients still had cognitive impairments at one month FU, our data also demonstrate the need for long-term psychological support and treatment for post COVID-19 patients.

Author Contributions

Conceptualization: Federica Alemanno, Sandro Iannaccone.

Data curation: Elise Houdayer, Anna Parma, Alfio Spina, Alessandra Scatolini.

Formal analysis: Elise Houdayer, Alfio Spina.

Investigation: Anna Parma, Alessandra Del Forno, Alessandra Scatolini, Sara Angelone, Luigia Brugliera, Andrea Tettamanti, Luigi Beretta.

Methodology: Federica Alemanno, Sandro Iannaccone.

Project administration: Sandro Iannaccone.

Resources: Sandro Iannaccone.

Supervision: Federica Alemanno, Luigi Beretta, Sandro Iannaccone.

Validation: Federica Alemanno.

Visualization: Federica Alemanno.

Writing – original draft: Federica Alemanno, Elise Houdayer.

Writing – review & editing: Federica Alemanno, Elise Houdayer, Sandro Iannaccone.

References

1. Carda S, Invernizzi M, Bavikatte G, Bensmaïl D, Bianchi F, Deltombe T, et al. The role of physical and rehabilitation medicine in the COVID-19 pandemic: the clinician's view. *Ann Phys Rehabil Med*. 2020. <https://doi.org/10.1016/j.rehab.2020.04.001> PMID: 32315802
2. Brugliera L, Spina A, Castellazzi P, Cimino P, Tettamanti A, Houdayer E, et al. Rehabilitation of COVID-19 patients. *J Rehabil Med*. 2020; 52: jrm00046. <https://doi.org/10.2340/16501977-2678> PMID: 32286674
3. Azim D, Nasim S, Kumar S, Hussain A, Patel S. Neurological Consequences of 2019-nCoV Infection: A Comprehensive Literature Review. *Cureus*. 2020; 12: e8790. <https://doi.org/10.7759/cureus.8790> PMID: 32601577
4. Iannaccone S, Castellazzi P, Tettamanti A, Houdayer E, Brugliera L, de Blasio F, et al. ROLE OF REHABILITATION DEPARTMENT FOR ADULT COVID-19 PATIENTS: THE EXPERIENCE OF THE SAN RAFFAELE HOSPITAL OF MILAN. *Arch Phys Med Rehabil*. 2020. <https://doi.org/10.1016/j.apmr.2020.05.015> PMID: 32505489
5. Pasqua F, Biscione GL, Crigna G, Gargano R, Cardaci V, Ferri L, et al. Use of functional independence measure in rehabilitation of inpatients with respiratory failure. *Respir Med*. 2009; 103: 471–476. <https://doi.org/10.1016/j.rmed.2008.09.007> PMID: 18977645
6. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol*. 2020; 77: 683–690. <https://doi.org/10.1001/jamaneurol.2020.1127> PMID: 32275288
7. Lechien JR, Chiesa-Estomba CM, De Siaty DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol*. 2020 [cited 30 Jun 2020]. <https://doi.org/10.1007/s00405-020-05965-1> PMID: 32253535
8. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. *Clin Infect Dis*. [cited 30 Jun 2020]. <https://doi.org/10.1093/cid/ciaa330> PMID: 32215618
9. Mariotto S, Savoldi A, Donadello K, Zanzoni S, Bozzetti S, Carta S, et al. Nervous system: subclinical target of SARS-CoV-2 infection. *J Neurol Neurosurg Psychiatry*. 2020 [cited 22 Jul 2020]. <https://doi.org/10.1136/jnnp-2020-323881> PMID: 32576611
10. Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. *Lancet Psychiatry*. 2020;0. [https://doi.org/10.1016/S2215-0366\(20\)30287-X](https://doi.org/10.1016/S2215-0366(20)30287-X) PMID: 32593341
11. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2020; 94: 55–58. <https://doi.org/10.1016/j.ijid.2020.03.062> PMID: 32251791
12. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features. *Radiology*. 2020; 201187. <https://doi.org/10.1148/radiol.2020201187> PMID: 32228363
13. Ellul M, Benjamin L, Singh B, Lant S, Michael B, Easton A, et al. Neurological Associations of COVID-19. Rochester, NY: Social Science Research Network; 2020 Apr. Report No.: ID 3589350. <https://doi.org/10.2139/ssrn.3589350>

14. Holmes EA, O'Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. *Lancet Psychiatry*. 2020. [https://doi.org/10.1016/S2215-0366\(20\)30168-1](https://doi.org/10.1016/S2215-0366(20)30168-1) PMID: 32304649
15. Wang C, Pan R, Wan X, Tan Y, Xu L, Ho CS, et al. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. *Int J Environ Res Public Health*. 2020; 17. <https://doi.org/10.3390/ijerph17051729> PMID: 32155789
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975; 12: 189–198. [https://doi.org/10.1016/0022-3956\(75\)90026-6](https://doi.org/10.1016/0022-3956(75)90026-6) PMID: 1202204
17. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005; 53: 695–699. <https://doi.org/10.1111/j.1532-5415.2005.53221.x> PMID: 15817019
18. Hamilton M. A RATING SCALE FOR DEPRESSION. *J Neurol Neurosurg Psychiatry*. 1960; 23: 56–62. <https://doi.org/10.1136/jnnp.23.1.56> PMID: 14399272
19. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. *Eur Neurol*. 1996; 36: 268–272. <https://doi.org/10.1159/000117270> PMID: 8864706
20. Al-Janabi OM, Panuganti P, Abner EL, Bahrani AA, Murphy R, Bardach SH, et al. Global Cerebral Atrophy Detected by Routine Imaging: Relationship with Age, Hippocampal Atrophy, and White Matter Hyperintensities. *J Neuroimaging Off J Am Soc Neuroimaging*. 2018; 28: 301–306. <https://doi.org/10.1111/jon.12494> PMID: 29314393
21. Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriat H, et al. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. *BMJ*. 2009; 339. <https://doi.org/10.1136/bmj.b2477> PMID: 19581317
22. Inzitari D, Simoni M, Pracucci G, Poggesi A, Basile AM, Chabriat H, et al. Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. *Arch Intern Med*. 2007; 167: 81–88. <https://doi.org/10.1001/archinte.167.1.81> PMID: 17210882
23. Davidson JR, Book SW, Colket JT, Tupler LA, Roth S, David D, et al. Assessment of a new self-rating scale for post-traumatic stress disorder. *Psychol Med*. 1997; 27: 153–160. <https://doi.org/10.1017/s0033291796004229> PMID: 9122295
24. Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia: A review based on up-to-date knowledge. *Am J Otolaryngol*. 2020; 41: 102581. <https://doi.org/10.1016/j.amjoto.2020.102581> PMID: 32563019
25. Sasannejad C, Ely EW, Lahiri S. Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms. *Crit Care Lond Engl*. 2019; 23: 352. <https://doi.org/10.1186/s13054-019-2626-z> PMID: 31718695
26. Wilcox ME, Brummel NE, Archer K, Ely EW, Jackson JC, Hopkins RO. Cognitive dysfunction in ICU patients: risk factors, predictors, and rehabilitation interventions. *Crit Care Med*. 2013; 41: S81–98. <https://doi.org/10.1097/CCM.0b013e3182a16946> PMID: 23989098
27. Herridge MS, Moss M, Hough CL, Hopkins RO, Rice TW, Bienvenu OJ, et al. Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. *Intensive Care Med*. 2016; 42: 725–738. <https://doi.org/10.1007/s00134-016-4321-8> PMID: 27025938
28. Hopkins RO, Weaver LK, Pope D, Orme JF, Bigler ED, Larson-LOHR V. Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. *Am J Respir Crit Care Med*. 1999; 160: 50–56. <https://doi.org/10.1164/ajrccm.160.1.9708059> PMID: 10390379
29. Mikkelsen ME, Christie JD, Lanken PN, Biester RC, Thompson BT, Bellamy SL, et al. The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury. *Am J Respir Crit Care Med*. 2012; 185: 1307–1315. <https://doi.org/10.1164/rccm.201111-2025OC> PMID: 22492988
30. Pfoh ER, Chan KS, Dinglas VD, Girard TD, Jackson JC, Morris PE, et al. Cognitive screening among acute respiratory failure survivors: a cross-sectional evaluation of the Mini-Mental State Examination. *Crit Care Lond Engl*. 2015; 19: 220. <https://doi.org/10.1186/s13054-015-0934-5> PMID: 25939482
31. Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). *JAMA*. 2001; 286: 2703–2710. <https://doi.org/10.1001/jama.286.21.2703> PMID: 11730446
32. Pisani MA, Inouye SK, McNicoll L, Redlich CA. Screening for preexisting cognitive impairment in older intensive care unit patients: use of proxy assessment. *J Am Geriatr Soc*. 2003; 51: 689–693. <https://doi.org/10.1034/j.1600-0579.2003.00215.x> PMID: 12752846

33. Inoue S, Hatakeyama J, Kondo Y, Hifumi T, Sakuramoto H, Kawasaki T, et al. Post-intensive care syndrome: its pathophysiology, prevention, and future directions. *Acute Med Surg*. 2019; 6: 233–246. <https://doi.org/10.1002/ams2.415> PMID: 31304024
34. Rawal G, Yadav S, Kumar R. Post-intensive Care Syndrome: an Overview. *J Transl Intern Med*. 2017; 5: 90–92. <https://doi.org/10.1515/jtim-2016-0016> PMID: 28721340
35. Nelliot A, Dinglas VD, O'Toole J, Patel Y, Mendez-Tellez PA, Nabeel M, et al. Acute Respiratory Failure Survivors' Physical, Cognitive, and Mental Health Outcomes: Quantitative Measures versus Semistructured Interviews. *Ann Am Thorac Soc*. 2019; 16: 731–737. <https://doi.org/10.1513/AnnalsATS.201812-851OC> PMID: 30844293
36. Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, et al. Long-term cognitive impairment after critical illness. *N Engl J Med*. 2013; 369: 1306–1316. <https://doi.org/10.1056/NEJMoa1301372> PMID: 24088092
37. Maydych V. The Interplay Between Stress, Inflammation, and Emotional Attention: Relevance for Depression. *Front Neurosci*. 2019; 13. <https://doi.org/10.3389/fnins.2019.00384> PMID: 31068783
38. Di Castelnuovo A, Bonaccio M, Costanzo S, Gialluisi A, Antinori A, Berselli N, et al. Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. *Nutr Metab Cardiovasc Dis NMCD*. 2020; 30: 1899–1913. <https://doi.org/10.1016/j.numecd.2020.07.031> PMID: 32912793
39. Brugliera L, Spina A, Castellazzi P, Cimino P, Arcuri P, Deriu MG, et al. Rehabilitative of COVID-19 patients with acute lower extremity Ischemia and amputation. *J Rehabil Med*. 2020; 52: jrm00094. <https://doi.org/10.2340/16501977-2714> PMID: 32720698
40. Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. *Neurology*. 2009; 73: 1738–1745. <https://doi.org/10.1212/WNL.0b013e3181c34b47> PMID: 19933974
41. Parker AM, Sricharoenchai T, Rappala S, Schneck KW, Bienvenu OJ, Needham DM. Posttraumatic stress disorder in critical illness survivors: a metaanalysis. *Crit Care Med*. 2015; 43: 1121–1129. <https://doi.org/10.1097/CCM.0000000000000882> PMID: 25654178
42. Murray H, Grey N, Wild J, Warnock-Parkes E, Kerr A, Clark DM, et al. Cognitive therapy for post-traumatic stress disorder following critical illness and intensive care unit admission. *Cogn Behav Ther*. 13. <https://doi.org/10.1017/S1754470X2000015X>
43. Carfi A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*. 2020; 324: 603. <https://doi.org/10.1001/jama.2020.12603> PMID: 32644129
44. Garrigues E, Janvier P, Kherabi Y, Bot AL, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *J Infect*. 2020; 81: e4–e6. <https://doi.org/10.1016/j.jinf.2020.08.029> PMID: 32853602
45. Mahase E. Long covid could be four different syndromes, review suggests. *BMJ*. 2020; 371: m3981. <https://doi.org/10.1136/bmj.m3981> PMID: 33055076